Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology

01-01-2015 | Research Article

A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products

Authors: A. Estévez-Braun, A. G. Ravelo, E. Pérez-Sacau, J. C. Lacal

Published in: Clinical and Translational Oncology | Issue 1/2015

Login to get access

Abstract

Background

Choline kinase alpha (ChoKα) is a critical enzyme in the synthesis of phosphatidylcholine, a major structural component of eukaryotic cell membranes. ChoKα is overexpressed in a large variety of tumor cells and has been proposed as a target for personalized medicine, both in cancer therapy and rheumatoid arthritis.

Materials and methods

Triterpene quinone methides (TPQ) bioactive compounds isolated from plants of the Celastraceae family and a set of their semisynthetic derivatives were tested against the recombinant human ChoKα. Those found active as potent enzymatic inhibitors were tested in vitro for antiproliferative activity against HT29 colorectal adenocarcinoma cells, and one of the active compounds was tested for in vivo antitumoral activity in mice xenographs of HT29 cells.

Results

Among 59 natural and semisynthetic TPQs tested in an ex vivo system, 14 were highly active as inhibitors of the enzyme ChoKα with IC50 <10 μM. Nine of these were potent antiproliferative agents (IC50 <10 μM) against tumor cells. At least one compound was identified as a new antitumoral drug based on its in vivo activity against xenographs of human HT-29 colon adenocarcinoma cells.

Conclusions

The identification of a new family of natural and semisynthetic compounds with potent inhibitory activity against ChoKα and both in vitro antiproliferative and in vivo antitumoral activity supports further research on these inhibitors as potential anticancer agents. Their likely role as antiproliferative drugs deserves further studies in models of rheumatoid arthritis.
Appendix
Available only for authorised users
Literature
1.
Lykidis A, Jackowski S. Regulation of mammalian cell membrane biosynthesis. Prog Nucleic Acid Res Mol Biol. 2001;65:361–93.PubMedCrossRef
2.
Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Progr Lipid Res. 2004;43:266–81.CrossRef
3.
Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs. 2001;4:419–26.PubMed
4.
Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martin-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005;65:5647–53.PubMedCrossRef
5.
Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, et al. Expression of ChoKα to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007;8:889–97.PubMedCrossRef
6.
Kwee SA, Hernandez B, Chan O, Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One. 2012;7(10):e46591.PubMedCentralPubMedCrossRef
7.
Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002;21:4317–22.PubMedCrossRef
8.
Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007;120:1721–30.PubMedCrossRef
9.
Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D’Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369–76.PubMedCrossRef
10.
Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramirez de Molina V, Cejas P, et al. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene. 2009;28:2425–35.PubMedCentralPubMedCrossRef
11.
Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010;70:2126–35.PubMedCentralPubMedCrossRef
12.
Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene. 1997;15:2289–301.PubMedCrossRef
13.
Rubio-Ruíz B, Conejo-García A, Rios-Marco P, Carrasco-Jiménez P, Segovia J, Marco C, et al. Design, synthesis, theorical calculations and biological evaluation of new no-symmetrical choline kinase inhibitors. Eur J Med Chem. 2012;50:154–62.PubMedCrossRef
14.
Martín-Cantalejo Y, Sáez B, Monterde MI, Murillo MT, Braña MF. Synthesis and biological activity of new bispyridinium salts of 4,4′-bispyridil-5,5′-perfluoroalkyl-2,2′-bisoxazoles. Eur J Med Chem. 2011;46:5662–7.PubMedCrossRef
15.
Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999;59:3112–8.PubMed
16.
Lacal JC, Campos JM Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. Mol Cancer Therap. doi:10.​1158/​1535-7163.​MCT-14-0531.
17.
Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, Nunez MC, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene. 2003;22:8803–12.PubMedCrossRef
18.
Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene. 2004;23:8247–59.PubMedCrossRef
19.
Ramirez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, Gomez del Pulgar T, Bandres E, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol. 2008;40:1753–63.PubMedCrossRef
20.
Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005;65:11034–43.PubMedCrossRef
21.
Bañez-Coronel M, Ramirez de Molina A, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA, et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets. 2008;8:709–19.PubMedCrossRef
22.
Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, et al. Differential role of choline kinase alpha and beta isoforms in human carcinogenesis. PLoS One. 2009;4:e7819.PubMedCentralPubMedCrossRef
23.
Gruber J, See Too WC, Wong MT, Lavie A, McSorley T, Konrad M. Balance of human choline kinase isoforms is critical for cell cycle regulation. Implications for the development of choline kinase-targeted cancer therapy. FEBS J. 2012;279:1915–28.PubMedCrossRef
24.
Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, et al. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene. 2011;30:3370–80.PubMedCentralPubMedCrossRef
25.
Hudson CS, Knegtel RM, Brown K, Charlton PA. Kinetic and mechanistic characterisation of choline kinase-α. Biochim Biophys Acta. 2013;1834:1107–16.PubMedCrossRef
26.
Trousil S, Carroll L, Kalusa A, Aberg O, Kaliszczak M, Aboagye EO. Design of symmetrical and nonsymmetrical N, N-dimethylamino pyridine derivatives as highly potent choline kinase alpha inhibitors. Med Chem Commun. 2013;4:693–6.CrossRef
27.
Sánchez Martín R, Campos JM, Conejo-García A, Cruz-López L, Báñez-Coronel M, Rodríguez-González A, et al. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line. J Med Chem. 2005;48:3354–63.PubMedCrossRef
28.
Milanese L, Espinosa A, Campos JM, Gallo MA, Entrena A. Insight into the inhibition of human choline kinase: homology modeling and molecular dynamics simulations. Chem Med Chem. 2006;1:1216–28.PubMedCrossRef
29.
Sahún-Roncero M, Rubio-Ruiz B, Saladino G, Conejo-García A, Espinosa A, Velázquez Campoy A, et al. The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor. Angew Chem Int Ed Engl. 2013;52:4582–6.PubMedCrossRef
30.
Schiaffino-Ortega S, López-Cara LC, Ríos-Marco P, Carrasco-Jimenez MP, Gallo MA, Espinosa A, et al. New non-symmetrical choline kinase inhibitors. Bioorg Med Chem. 2013;22:7146–54.CrossRef
31.
Conejo-Garcia A, Bañez-Coronel M, Sanchez-Martin RM, Rodriguez-Gonzalez A, Ramos A, Ramirez de Molina A, et al. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J Med Chem. 2004;47:5433–40.PubMedCrossRef
32.
Zimmerman T, Moneriz C, Diez A, Bautista JM, Gómez del Pulgar T, Cebrián A, et al. RSM-932A is a promising synergistic inhibitor of the choline kinase of plasmodium falciparum. Antimicrob Agents Chemother. 2013;57:5878–88.PubMedCentralPubMedCrossRef
33.
34.
Morris GM, Goodsell DS, Hallyday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and a empirical binding free energy function. J Comput Chem. 1998;19:1639–62.CrossRef
35.
36.
Alvarenga N, Ferro E. Bioactive triterpenes and related compounds from Celastraceae. Stud Nat Prod Chem. 2005;30:635–702 [bioactive natural products (part K)].CrossRef
37.
Gutierrez F, Estevez-Braun A, Ravelo AG, Astudillo L, Zarate R. Terpenoids from the Medicinal Plant Maytenus ilicifolia. J Nat Prod. 2007;70:1049–52.PubMedCrossRef
38.
Ravelo A, Estévez-Braun A, Chávez H, Pérez-Sacau E, Mesa-Siverio D. Recent studies on natural products as anticancer agents. Curr Top Med Chem. 2004;4:241–65.PubMedCrossRef
39.
Chavez H, Rodriguez G, Estevez-Braun A, Ravelo AG, Estevez-Reyes R, Gonzalez AG, et al. Macrocarpins A-D, new cytotoxic nor-triterpenes from Maytenus macrocarpa. Bioorg Med Chem Lett. 2000;10:759–62.PubMedCrossRef
40.
Chavez H, Estevez-Braun A, Ravelo AG, Gonzalez AG. New phenolic and quinone-methide triterpenes from maytenus amazonica. J Nat Prod. 1999;62:434–6.PubMedCrossRef
41.
Chavez H, Valdivia E, Estevez-Braun A, Ravelo AG. Structure of new bioactive triterpenes related to 22β-hydroxytingenone. Tetrahedron. 1998;54:13579–90.CrossRef
42.
Mesa-Siverio D, Chavez H, Estevez-Braun A, Ravelo AG, Cheiloclines A-I. First examples of octacyclic sesquiterpene-triterpene hetero-Diels-Alder adducts. Tetrahedron. 2005;61:429–36.CrossRef
43.
Oramas-Royo S, Chávez H, Martín-Rodríguez P, Fernández-Pérez L, Ravelo AG, Estévez-Braun A. Cytotoxic Triterpenoids from Maytenus retusa. J Nat Prod. 2010;73:2029–34.PubMedCrossRef
44.
Nakanishi K, Takahashi Y, Budzikiewicz H. Pristimerine. Spectroscopic properties of the dienone-phenol-type rearrangement products and other derivatives. J Org Chem. 1965;30:1729–34.CrossRef
45.
Hong BS, Allali-Hassani A, Tempel W, Finerty PJ, MacKenzie F, Dimov S, et al. Crystal structures of human choline kinase isoforms in complex with hemicholinium-3. J Biol Chem. 2010;285:16330–4.PubMedCentralPubMedCrossRef
Metadata
Title
A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products
Authors
A. Estévez-Braun
A. G. Ravelo
E. Pérez-Sacau
J. C. Lacal
Publication date
01-01-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1260-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits